Press Releases
Public Relations: Andrew Noble
DNAnexus Wins BioTech Breakthrough Award For BioInformatics Solution of the Year
Annual Awards Program Recognizes Innovation in the Global Life Science and Biotechnology Industries.
DNAnexus Strengthens Leadership Team to Drive Ongoing Product Innovation and Commercial Growth
Company appoints healthcare technology industry veterans Nupura Kolwalkar as Chief Product Officer and Bill Madigan as Chief Commercial Officer.
DNAnexus and Galatea Bio Launch Collaboration to Enhance Precision Medicine with Advanced Genetic Tools for Underserved Populations
Under the new agreement, Galatea Bio will use DNAnexus' Precision Health Data Cloud to increase the availability and speed of the analysis of its diverse non-European datasets. Importantly, this collaboration will allow DNAnexus' extensive network of more than 48,000 users across 48 countries to potentially leverage Galatea’s advanced local ancestry and ancestry-adjusted PRS (polygenic risk score) algorithms.
UK Biobank and DNAnexus Collaboration Earns Bio-IT World 2024 Innovative Best Practices Global Impact Award for 500,000 Whole Genomes Data Release
DNAnexus and Oracle Collaborate to Advance Precision Health
We are excited to announce we have teamed up with Oracle to advance precision health by connecting our respective ecosystems. The DNAnexus platform will be seamlessly available to global Oracle Cloud Infrastructure, Oracle Health, and Oracle Database customers. In addition, customers will be able to use OCI integration services for their healthcare applications. DNAnexus customers will be able to leverage Oracle’s expertise in accelerating AI pipelines and its industry partnerships to bring global customers even faster genomic analysis and better AI models.
DNAnexus Adds NVIDIA NIM and CUDA-X Microservices to Precision Health Data Cloud to Accelerate Drug Discovery and Improve Patient Care
New Universal DeepVariant is one microservice compatible across multiple sequencing platforms and is designed to deliver more than 50x acceleration compared to CPU
DNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD Summit
Co-founder of Ovation to share how researchers are using DNAnexus’ Precision Health Data Cloud to streamline analysis, identify optimal therapeutic targets, and advance drug discovery.
DNAnexus and Curio Bioscience Announce Collaboration to Streamline and Simplify Data Analysis for Large-Scale Spatial Transcriptomics Projects
Combination of Curio Seeker with Precision Health Data Cloud provides scientists with a secure and scalable solution for managing and sharing high-resolution, spatially resolved gene expression data.
DNAnexus and LORENZ Partner to Enable Collaborative Regulatory Submission Validation and Scientific Review in the Cloud via Trusted Regulatory Spaces
Companies have joined with industry leaders and FDA on Project PRISM to advance solutions that can improve the submission, review and ease of communication for human drug and biologics applications.
Element Biosciences and DNAnexus® Announce Collaboration to Advance Multi-Omics Analysis
Direct integration allows customers to stream data from Element’s AVITI™ System directly to DNAnexus.
DNAnexus and TMA Precision Health Join Forces to Improve Diagnostics and Treatment Options for Rare Diseases
Collaboration with TMA. Trusted research environment provides secure access to high-quality, de-identified whole genome sequencing data and associated medical records.
DNAnexus and Intelliseq Combine Efforts to Add Automated Genomic Variant Interpretation and Clinical Reporting Capabilities to Precision Health Data Cloud
Integrated and Intuitive workflows designed to generate actionable insights into somatic cancers and hereditary diseases
DNAnexus and Ovation Team Up to Unlock Large-Scale Precision Health Datasets to Accelerate Drug Discovery and Drive Scientific Breakthroughs
Life science researchers can use DNAnexus’ Precision Health Data Cloud to analyze high-value omics data and quickly gain insights that pave the way for innovative discoveries.
DNAnexus and Discovery Life Sciences to Streamline Precision Health Data Analysis
Automated workflow enhances genomics biomarker analysis, reduces risk, and accelerates project timelines.
DNAnexus to Showcase the Power of the Precision Health Data Cloud at ASHG 2023 Annual Meeting
Leading human geneticists and bioinformaticians to share latest multimodal data-driven insights that can help accelerate collaborative discovery
DNAnexus-enabled UK Biobank Research Analysis Platform Surpasses 5,000 Users in Two Years
World’s largest biomedical research resource now features more than 28 PB of data to help accelerate scientific discovery and improve human health
DNAnexus Announces Appointment of Thomas Laur as CEO
Proven healthcare executive brings decades of experience leading successful software, data, and services companies. Richard Daly remains actively involved as a member of the Board of Directors
DNAnexus and BigOmics Analytics Join Forces to Improve Proteomics and Transcriptomics Data Visualization and Interpretation
Complete collaborative environment with intuitive interface addresses common analysis challenges to help accelerate transition from scientific discovery to data-driven precision medicine
DNAnexus Platform Enables Researchers to Access and Analyze Biomedical Data for Largest Health Research Program in Mexico
DNAnexus Platform Enables Researchers to Access and Analyze Biomedical Data for Largest Health Research Program in Mexico
DNAnexus Named 2023 Company of the Year for Global Precision Medicine Informatics Industry
Frost & Sullivan recognizes the company for its ongoing commitment to empowering customers to derive insights from large-scale genomics, multi-omics, and clinical datasets
DNAnexus Platform Streamlines Access and Analysis for Large-Scale Proteomics Data
Company to host webinar featuring tips for managing large-scale proteomics data on UK Biobank Research Analysis Platform
DNAnexus Adds Jovan Willford to Board of Directors
Veteran healthcare technology executive brings decades of operational experience applying advanced data analytics to enable the healthcare ecosystem.
Parse Biosciences Announces Cloud Analysis Platform to Simplify Single Cell Analysis
DNAnexus to Showcase Platform Scalability, Versatility, and Security at ASHG 2022 Annual Meeting
DNAnexus Adds Jeff Margolis to Board of Directors
DNAnexus Appoints Chief Commercial Officer to Accelerate Global Adoption of Leading Biomedical Data-Driven Technology Platform
DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program
DNAnexus Named One of the 100 Best Workplaces for Innovators by Fast Company
DNAnexus and Twist Bioscience Collaborate to Provide Data Analysis Software for NGS Workflow
DNAnexus Secures $200 Million Funding Led by Blackstone Growth
News
The Rise and Importance of Population-Scale Genome Programs
With the wealth of population-scale projects going on, we have entered a golden age of genomics. Based on efforts such as the All of Us program in the U.S. and the UK Biobank, among many others, we are poised to discover more than we ever knew about natural genetic diversity, what’s considered “normal” human biology, and the continuum of health and disease.
World’s largest genetic project opens the door to new era for treatments and cures: UK Biobank’s major milestone
In a momentous landmark for medical research, UK Biobank has today unveiled incredible new data from whole genome sequencing of its half a million participants. This is set to drive the discovery of new diagnostics, treatments and cures and, uniquely, is available to approved researchers worldwide, via a protected database containing only de-identified data (e.g. name, address, date of birth, name of GP and more stripped out).
DNAnexus included in Fast Company's 10 most innovative biotech companies of 2023
Among the 2023 Most Innovative Companies in Biotech, Fast Company is recognizing breakthroughs in DNA sequencing and spatial transcriptomics, along with innovations in biological-specimen sourcing, cell-separation technology, and the production of synthetic antibodies.